WO2019059550A3 - COMPOSITION POUR PRÉVENIR OU TRAITER L'OBÉSITÉ CONTENANT UN COMPLÉMENT DESTINÉ À RÉDUIRE LA MASSE ADIPEUSE ET DU β-GLUCANE POUR PRINCIPES ACTIFS - Google Patents

COMPOSITION POUR PRÉVENIR OU TRAITER L'OBÉSITÉ CONTENANT UN COMPLÉMENT DESTINÉ À RÉDUIRE LA MASSE ADIPEUSE ET DU β-GLUCANE POUR PRINCIPES ACTIFS Download PDF

Info

Publication number
WO2019059550A3
WO2019059550A3 PCT/KR2018/009976 KR2018009976W WO2019059550A3 WO 2019059550 A3 WO2019059550 A3 WO 2019059550A3 KR 2018009976 W KR2018009976 W KR 2018009976W WO 2019059550 A3 WO2019059550 A3 WO 2019059550A3
Authority
WO
WIPO (PCT)
Prior art keywords
glucan
supplement
preventing
composition
active ingredients
Prior art date
Application number
PCT/KR2018/009976
Other languages
English (en)
Korean (ko)
Other versions
WO2019059550A2 (fr
Inventor
이종대
류제필
최승인
김제경
장용만
김민지
박은지
양철수
Original Assignee
주식회사 큐젠바이오텍
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180101389A external-priority patent/KR102133218B1/ko
Application filed by 주식회사 큐젠바이오텍 filed Critical 주식회사 큐젠바이오텍
Priority to JP2020515700A priority Critical patent/JP2020533394A/ja
Priority to CN201880060863.4A priority patent/CN111107844A/zh
Priority to US16/609,734 priority patent/US20200206291A1/en
Publication of WO2019059550A2 publication Critical patent/WO2019059550A2/fr
Publication of WO2019059550A3 publication Critical patent/WO2019059550A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pour prévenir ou traiter l'obésité, cette composition contenant un complément destiné à réduire la masse adipeuse et du β-glucane pour principes actifs.
PCT/KR2018/009976 2017-09-19 2018-08-29 COMPOSITION POUR PRÉVENIR OU TRAITER L'OBÉSITÉ CONTENANT UN COMPLÉMENT DESTINÉ À RÉDUIRE LA MASSE ADIPEUSE ET DU β-GLUCANE POUR PRINCIPES ACTIFS WO2019059550A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2020515700A JP2020533394A (ja) 2017-09-19 2018-08-29 体脂肪減少補助剤およびベータグルカンを有効成分とする肥満の予防または治療用組成物
CN201880060863.4A CN111107844A (zh) 2017-09-19 2018-08-29 包含体脂减少助剂及β-葡聚糖作为有效成分的肥胖预防或治疗用组合物
US16/609,734 US20200206291A1 (en) 2017-09-19 2018-08-29 Composition for preventing or treating obesity, comprising supplement for reducing body fat and b-glucan as active ingredients

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20170120338 2017-09-19
KR10-2017-0120338 2017-09-19
KR1020180101389A KR102133218B1 (ko) 2017-09-19 2018-08-28 체지방 감소 보조제 및 베타글루칸을 유효성분으로 하는 비만 예방 또는 치료용 조성물
KR10-2018-0101389 2018-08-28

Publications (2)

Publication Number Publication Date
WO2019059550A2 WO2019059550A2 (fr) 2019-03-28
WO2019059550A3 true WO2019059550A3 (fr) 2019-05-09

Family

ID=65809689

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/009976 WO2019059550A2 (fr) 2017-09-19 2018-08-29 COMPOSITION POUR PRÉVENIR OU TRAITER L'OBÉSITÉ CONTENANT UN COMPLÉMENT DESTINÉ À RÉDUIRE LA MASSE ADIPEUSE ET DU β-GLUCANE POUR PRINCIPES ACTIFS

Country Status (1)

Country Link
WO (1) WO2019059550A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006191830A (ja) * 2005-01-12 2006-07-27 Unitika Ltd 脂肪の蓄積を抑制する食品
KR20080064703A (ko) * 2007-01-04 2008-07-09 주식회사 글루칸 β-글루칸 및 길경 추출물을 유효성분으로 포함하는 항비만조성물
KR20100046348A (ko) * 2008-10-27 2010-05-07 (주)큐젠바이오텍 면역 증진 및 다이어트 효과를 갖는 천연 바이오폴리머의 다이어트 식품으로써의 용도
KR20110027717A (ko) * 2008-05-29 2011-03-16 메-에크 아에스 1,3／1,6 베타 글루칸을 포함하는 체중 감량용 조성물
KR20140073631A (ko) * 2012-11-30 2014-06-17 (주)아모레퍼시픽 잎새버섯 자실체 추출물을 포함하는 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006191830A (ja) * 2005-01-12 2006-07-27 Unitika Ltd 脂肪の蓄積を抑制する食品
KR20080064703A (ko) * 2007-01-04 2008-07-09 주식회사 글루칸 β-글루칸 및 길경 추출물을 유효성분으로 포함하는 항비만조성물
KR20110027717A (ko) * 2008-05-29 2011-03-16 메-에크 아에스 1,3／1,6 베타 글루칸을 포함하는 체중 감량용 조성물
KR20100046348A (ko) * 2008-10-27 2010-05-07 (주)큐젠바이오텍 면역 증진 및 다이어트 효과를 갖는 천연 바이오폴리머의 다이어트 식품으로써의 용도
KR20140073631A (ko) * 2012-11-30 2014-06-17 (주)아모레퍼시픽 잎새버섯 자실체 추출물을 포함하는 조성물

Also Published As

Publication number Publication date
WO2019059550A2 (fr) 2019-03-28

Similar Documents

Publication Publication Date Title
PH12019502279A1 (en) Cleaning compositions and uses thereof
MY186217A (en) Mixture of hmos
MX2019013070A (es) Composiciones de limpieza mejoradas.
WO2015058664A8 (fr) Utilisation d'icariine pour préparer un médicament destiné à prévenir ou à traiter une baisse des cellules sanguines
WO2017022962A8 (fr) Composition pour la prévention ou le traitement d'une maladie immunitaire, comprenant un inhibiteur de la rip kinase en tant que principe actif
EP4218736A3 (fr) Compositions à base de 15-hepe
EP4378535A3 (fr) Formulations antibiotiques pour la douleur lombaire
WO2019111115A3 (fr) Oligosaccharides du lait humain pour le traitement de la migraine
WO2015066302A3 (fr) Compositions, méthodes d'utilisation et méthodes de traitement
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
WO2012091440A3 (fr) Composition pour l'amélioration, le traitement et la prévention de troubles de la motilité du tractus gastro-intestinal
WO2018093238A3 (fr) Composition comprenant en tant qu'ingrédient actif une souche présentant une excellente aptitude à produire de l'acide formique pour prévenir ou traiter l'obésité ou des syndromes métaboliques provoqués par l'obésité
WO2016142708A3 (fr) Composition pharmaceutique
MX2012008890A (es) Composicion de combinacion, que comrpende como ingrediente activo l-carnitina o propionil l-carnitina, para la prevencion o tratamiento de insuficiencia venosa cronica.
PL4044822T3 (pl) Produkty czekoladowe, składniki, sposoby i zastosowania
WO2011136573A3 (fr) Hydrolysat de levure ayant des effets de traitement de l'obésité et une activité antioxydante
WO2019098811A3 (fr) Composition pour prévenir, soulager ou traiter des maladies de perte osseuse, comprenant cyclo(his-pro) (chp)
WO2016178510A3 (fr) Composition pharmaceutique pour la prévention ou le traitement de la leucémie résistant au gleevec, contenant, comme principe actif, du ginsénoside f1 ou rg3
WO2016135456A3 (fr) Aortopathie
WO2019059550A3 (fr) COMPOSITION POUR PRÉVENIR OU TRAITER L'OBÉSITÉ CONTENANT UN COMPLÉMENT DESTINÉ À RÉDUIRE LA MASSE ADIPEUSE ET DU β-GLUCANE POUR PRINCIPES ACTIFS
CA3041260C (fr) Composition renfermant de l'allulose servant a promouvoir l'excretion des lipides vegetaux du corps
WO2016186335A3 (fr) Composition orale pour la prévention et le traitement des caries contenant de l'extrait de racine de mûrier et de l'extrait de euonymus alatus en tant que principes actifs
PH12018502568A1 (en) Composition comprising at least one enzyme and at least one microbicidal molecule for the prevention or treatment of post-implant infections
EP3727397A4 (fr) Composition et méthode pour traiter, soulager ou prévenir la douleur neuropathique, contenant de la glycérylphosphorylcholine en tant que principe actif
EP3600306A4 (fr) Agent de prévention de la myopie, de traitement de la myopie, et/ou de prévention de la progression de la myopie comprenant du tiotropium en tant que principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18858053

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020515700

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18858053

Country of ref document: EP

Kind code of ref document: A2